Powered by: Motilal Oswal
2026-11-16 02:53:02 pm | Source: Accord Fintech
Natco Pharma surges despite reporting 61% drop in Q2 consolidated net profit
Natco Pharma surges despite reporting 61% drop in Q2 consolidated net profit

Natco Pharma is currently trading at Rs. 825.00, up by 12.75 points or 1.57% from its previous closing of Rs. 812.25 on the BSE.

The scrip opened at Rs. 822.45 and has touched a high and low of Rs. 882.45 and Rs. 809.00 respectively. So far 362294 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1216.20 on 12-May-2026 and a 52 week low of Rs. 774.00 on 22-Oct-2026.

Last one week high and low of the scrip stood at Rs. 882.45 and Rs. 779.65 respectively. The current market cap of the company is Rs. 16128.93 crore.

The promoters holding in the company stood at 49.39%, while Institutions and Non-Institutions held 22.15% and 28.46% respectively.

Natco Pharma has reported 71.41% drop in its net profit at Rs 143.20 crore for the second quarter ended September 30, 2026 (Q2FY27) as compared to Rs 500.90 crore for the same quarter in the previous year. The total income of the company has decreased by 34.09% at Rs 894.80 crore for Q2FY27 as compared to Rs 1,357.60 crore for the corresponding quarter of the previous year.

On consolidated basis, the company has reported 60.92% drop in its net profit at Rs 202.60 crore for the quarter ended September 30, 2026 as compared to Rs 518.40 crore for the same quarter in the previous year. The total income of the company decreased by 30.32% at Rs 1,019.40 crore for Q2FY27 as compared to Rs 1,463.00 crore for the corresponding quarter previous year.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here